MRSN vs. TRVI, VYGR, LFVN, ITOS, IMMP, AQST, YMAB, ATYR, OLMA, and CMPX
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Trevi Therapeutics (TRVI), Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Immutep (IMMP), Aquestive Therapeutics (AQST), Y-mAbs Therapeutics (YMAB), Atyr PHARMA (ATYR), Olema Pharmaceuticals (OLMA), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs.
Mersana Therapeutics (NASDAQ:MRSN) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
Mersana Therapeutics received 155 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 65.96% of users gave Mersana Therapeutics an outperform vote while only 65.52% of users gave Trevi Therapeutics an outperform vote.
In the previous week, Mersana Therapeutics had 12 more articles in the media than Trevi Therapeutics. MarketBeat recorded 13 mentions for Mersana Therapeutics and 1 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.22 beat Mersana Therapeutics' score of -0.32 indicating that Trevi Therapeutics is being referred to more favorably in the news media.
Mersana Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 11.8% of Mersana Therapeutics shares are held by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Trevi Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mersana Therapeutics presently has a consensus target price of $5.57, indicating a potential upside of 800.65%. Trevi Therapeutics has a consensus target price of $9.31, indicating a potential upside of 147.67%. Given Mersana Therapeutics' higher possible upside, analysts clearly believe Mersana Therapeutics is more favorable than Trevi Therapeutics.
Trevi Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -214.20%. Trevi Therapeutics' return on equity of -63.31% beat Mersana Therapeutics' return on equity.
Summary
Trevi Therapeutics beats Mersana Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 1/20/2025 by MarketBeat.com Staff
Free MRSN Stock Alerts